>

Sanford Zweifach - COMPUGEN Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

 2,599  91.00  3.63%

  Director
Mr. Sanford Zweifach was appointed Director at Compugen Ltd. effective June 11, 2018. His work experience includes the following roles Founder and Chief Executive Officer of Nuvelution Pharma, Inc., Founder and Chief Executive Officer of Ascendancy Healthcare, Inc., Partner at Reedland Capital Partners, Chief Executive Officer of Pathways Diagnostics, Managing Director and Chief Financial Officer of Bay City Capital, President and Chief Financial Officer of Epoch Biosciences, Chairman of Lyric Pharmaceuticals Inc. and IMIDomics, S.L. and Director of Realm Therapeutics, Inc. He holds a BS degree in Biology from University of California San Diego and a MS degree in Physiology from University of California, Davis. He is a Certified Public Accountant.
Age: 60  Director Since 2018      
(972) 3 765 8555  www.cgen.com

Management Efficiency

The company has accumulated 3.58 M in total debt with debt to equity ratio (D/E) of 9.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. COMPUGEN has Current Ratio of 7.05 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Daniel PelegSOLEGREEN LTD
2017
Itzhak KrinskyKAMADA
2017
Ronit CohenSOLEGREEN LTD
2013
Joseph EldorKADIMASTEM
2018
Revital SternRaffKITOV PHARMA LTD
2017
Chava ToaffSOLEGREEN LTD
2018
Shlomo FedidaSOLEGREEN LTD
2018
Shmuel RubinsteinKAMADA
2017
Yoav KedarSOLEGREEN LTD
2012
Yodfat BuchrisPROTALIX BIOTHERAP
2007
Ziv KopKAMADA
2005
Kinneret SavitzkyEVOGENE LTD
2010
Asaf FrumermanKAMADA
2017
Simcha SadanEVOGENE LTD
2006
Moran SherfBlauKITOV PHARMA LTD
2013
Michael AnghelEVOGENE LTD
2007
Estery GilozRanKAMADA
2014
David SultanKADIMASTEM
2017
Kinneret SavitskyEVOGENE LTD
2010
Leon RecanatiEVOGENE LTD
2005
Leah BruckKITOV PHARMA LTD
2016

Company Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 61 people.COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 61 people.

COMPUGEN Leadership Team

Joshua Shemer, Independent External DirectorView
Michal Preminger, DirectorView
Paul Sekhri, Chairman of the BoardView
Dov Hershberg, DirectorView
Martin Gerstel, Chairman of the BoardView
Arie Ovadia, Independent External DirectorView
Zurit Levine, Vice President - Research and DiscoveryView
Eran Perry, DirectorView
Ari Krashin, Chief Financial OfficerView
Sanford Zweifach, DirectorView
Gilead Halevy, DirectorView
Anat CohenDayag, President, Chief Executive Officer, DirectorView
Ruth Arnon, Independent DirectorView
Kinneret Savitsky, DirectorView
Henry Adewoye, Chief Medical OfficerView
Yair Aharonowitz, Independent External DirectorView
JeanPierre Bizzari, DirectorView
John Hunter, VP of Antibody RandD and Site Head of Compugen USA IncView

Stock Performance Indicators

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and KAMADA. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page